EXHIBIT 10(m)And Distribution Agreement • December 13th, 2010 • Cel Sci Corp • Biological products, (no disgnostic substances)
EX-10.208 2 dex10208.htm FORM OF LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT EXECUTION COPYAnd Distribution Agreement • May 5th, 2020 • New York
CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT (INDICATED BY ASTERISKS) HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER 17 C.F.R. SECTIONS...And Distribution Agreement • August 5th, 2004 • Lindows Inc • Services-prepackaged software • California
EX-10.22 12 dex1022.htm LICENSING AND DISTRIBUTION AGREEMENT CONFIDENTIALAnd Distribution Agreement • May 5th, 2020
Exhibit 10.22 LICENSING & DISTRIBUTION AGREEMENT by and between Parthus Technologies plc. and Silaria Corporation This DEVELOPMENT, LICENSING & DISTRIBUTION AGREEMENT with an Effective Date of September 30, 2002, is made by and between Silaria Ltd., a Republic of Ireland company doing business at Dominic Court, 41 Dominic Street, Dublin 1, Ireland (“Silaria”), and Parthus Technologies, Inc., a Republic of Ireland corporation qualified to do business in California and doing business at 32-34 Harcourt Street, Dublin 2, Ireland and at 2033 Gateway Place, Suite 150, San Jose, CA 95110 (“Licensee”). Silaria and Licensee are referred to individually as a “Party” and collectively as the “Parties.” Recitals A. Silaria designs, develops, and markets configurable microprocessor technology, in the form of semiconductor design Intellectual Property (IP). B. Licensee has developed and markets a broad portfolio of complete solutions in the form of platform-level semiconductor design Intellectual Pro
ASSET PURCHASE, LICENSE, AND DISTRIBUTION AGREEMENT MARKED, REDACTED COPY ASSET PURCHASE, LICENSE, AND DISTRIBUTION AGREEMENTAnd Distribution Agreement • August 16th, 1999 • Vysis Inc • In vitro & in vivo diagnostic substances • California
ADDENDUM TO NOVEMBER 15, 2000 TRADEMARK, SUPPLY AND DISTRIBUTION AGREEMENT between and among ALLIED DOMECQ INTERNATIONAL HOLDINGS BV and ALLIED DOMECQ SPIRITS & WINE USA, INC. doing business as Allied Domecq Spirits, USA AND SPIRITS INTERNATIONAL NV...And Distribution Agreement • July 26th, 2002 • Allied Domecq PLC
Addendum to Trademark, Supply and Distribution Agreement dated November 15, 2000 (the "Agreement"), by and among SPIRITS INTERNATIONAL N.V., a Netherlands corporation ("SPI NV") and S.P.I. SPIRITS (CYPRUS) LIMITED, a Cyprus corporation ("SCL"; SPI NV and SCL are sometimes collectively referred to herein as "Spirits") and ALLIED DOMECQ INTERNATIONAL HOLDINGS BV, a Netherlands corporation ("ADIHBV") and ALLIED DOMECQ SPIRITS & WINE USA, INC., a Michigan corporation doing business as Allied Domecq Spirits, USA ("ADSUSA"; ADIHBV and ADSUSA are sometimes collectively referred to herein as "AD")
MARKETING, SALES, AND DISTRIBUTION AGREEMENTAnd Distribution Agreement • May 5th, 2020 • Delaware
This Marketing, Sales, and Distribution Agreement (the “Agreement”) is effective September 26, 2015 (the “Effective Date”) by and between SenesTech. Inc., a Nevada corporation with its headquarters located at 3140 N. Caden Court, Suite 1, Flagstaff, AZ 86004, referred to herein as “SenesTech,” and NeoVenta Solutions. Inc., a California corporation with its principal office located at 461 S. Milpitas Blvd.. Suite 1, Milpitas. CA 95035, referred to herein as “NeoVenta.”
MANUFACTURING AND DISTRIBUTION AGREEMENTAnd Distribution Agreement • December 8th, 2014 • Brisset Beer International, Inc. • Crude petroleum & natural gas • Quebec
BIERE BRISSET INTERNATIONAL INC., corporation duly incorporated and existing under the Canada Business Corporations Act, having its registered office at 2199, de Maisonneuve Boulevard West, in the city of Montreal, province of Quebec, H2K 2E4, represented by its President, Mr. Stéphane Pilon, and its Secretary, Mr. Pol Brisset, duly authorized for the purposes hereof as stated;
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. SALES PROMOTION AND...And Distribution Agreement • August 6th, 2020 • Nabriva Therapeutics PLC • Pharmaceutical preparations • New Jersey
This Sales Promotion and Distribution Agreement (this “Agreement”), dated as of July 15, 2020 (the “Effective Date”), is entered into by and among NABRIVA THERAPEUTICS IRELAND DESIGNATED ACTIVITY COMPANY, an Irish designated activity company (“Distributor”), with its registered office at Alexandra House, Office 225/227, The Sweepstakes, Ballsbridge, Dublin 4, D04 C7H2, Ireland, MSD INTERNATIONAL GMBH, a [•] (“MSD”), with offices at [•], and, solely for purposes of Sections 7.1 and 7.2, MERCK SHARP & DOHME CORP., a New Jersey corporation (“Supplier”), with offices at 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA. Distributor, MSD, and Supplier are each referred herein as a “Party” and collectively as the “Parties.”
INTERNATIONAL OFF-TAKE AND DISTRIBUTION AGREEMENT BETWEEN GEVO, INC and SASOL CHEMICAL INDUSTRIES LIMITED, ACTING THROUGH ITS SASOL SOLVENTS DIVISIONAnd Distribution Agreement • November 2nd, 2011 • Gevo, Inc. • Industrial organic chemicals • England
This International Off-take and Distribution Agreement (this “Agreement”) is made and entered into as of this 29th day of July 2011 (the “Effective Date”), by and between Gevo, Inc., a Delaware corporation having its principal address at 345 Inverness Drive South, Building C, Suite 310, Englewood, Colorado 80112 (“Manufacturer” or “Gevo”), and Sasol Chemical Industries Limited, acting through its Sasol Solvents Division, a South African company having its principal address at 1 Sturdee Avenue, Rosebank, 2196 Republic of South Africa (“Distributor” or “Sasol”) (each individually referred to as a “Party” and collectively, the “Parties”).
ARTICLE 1 DEFINTIONSAnd Distribution Agreement • March 30th, 2001 • Asv Inc /Mn/ • Construction machinery & equip • Minnesota
EX-10.58 4 dex1058.htm MANUFACTURING AND DISTRIBUTION AGREEMENT NOTE: Portions of this Exhibit are the subject of a Confidential Treatment Request by the Registrant to the Securities and Exchange Commission (the “Commission”). Such portions have been...And Distribution Agreement • May 5th, 2020 • New Jersey
This Manufacturing and Distribution Agreement (“Agreement”) is entered into as of this 27th of October, 2005 (the “Effective Date”) by and between PRINCETON BIOMEDITECH CORPORATION, a New Jersey Corporation (“PBM”), having its principal place of business at 4242 U.S. Route 1, Monmouth Junction, New Jersey 08852, and NANOGEN, INC., a Delaware Corporation (“NANOGEN”), having its principal place of business at 10398 Pacific Center Court, San Diego, California 92121.
SECOND AMENDMENT TO THE EXCLUSIVE RAGNAROK ONLINE LICENSE AND DISTRIBUTION AGREEMENTAnd Distribution Agreement • April 27th, 2012 • GRAVITY Co., Ltd. • Services-business services, nec
THIS SECOND AMENDMENT was made and entered into on this 5th day of March, 2012 (“Effective Date”), by and between Gravity Co., Ltd. (“Licensor”), a corporation duly organized and existing under the laws of the Republic of Korea and having its Principle office at 15F, Nuritkum Square BIZ Tower, 1605, Sangam-Dong, Mapo-Gu Seoul and AsiaSoft Corporation Public Co., Ltd. (“Licensee”), a corporation duly organized and existing under the laws of the Thailand and having its principal office at 9 U.M. Tower, 28th Floor, Room 9/283-5, Ramkhamhaeng Road, Suanluang, Bangkok 10250, Thailand.
Exhibit 2.1 ASSET PURCHASE, LICENSE, AND DISTRIBUTION AGREEMENT BY AND BETWEENAnd Distribution Agreement • July 30th, 1999 • Applied Imaging Corp • Surgical & medical instruments & apparatus • California
BANK OF COMMUNICATIONS SCHRODER FUND MANAGEMENT CO., LTD ANDAnd Distribution Agreement • February 26th, 2016 • Hong Kong
LICENSE, PRODUCT PRODUCTION, AND DISTRIBUTION AGREEMENT, and Distribution Agreement • August 14th, 2008 • Biotime Inc • Biological products, (no disgnostic substances) • California
This Agreement is made and entered into this 19th day of June 2008 (the "EFFECTIVE DATE"), by and among LifeLine Cell Technology, LLC, a California limited liability company with offices located at 2595 Jason Court, Oceanside, CA 92056 (“Lifeline”), BioTime, Inc., a California corporation with offices located at 1301 Harbor Bay Parkway, Suite 100 Alameda, California 94502 (“BioTime”), and Embryome Sciences, Inc., a California corporation and subsidiary of BioTime with offices located at 1301 Harbor Bay Parkway, Suite 100, Alameda, California 94502 (“ES”) Lifeline, BioTime, and ES are sometimes hereinafter referred to as the “Parties.”
Exclusive Licensing, Co-packing, and Distribution Agreement, and Distribution Agreement • October 20th, 2023 • ALKALINE WATER Co INC • Wholesale-groceries & related products • Arizona
This Exclusive Licensing, Co-packing, and Distribution Agreement ("Agreement"), dated as of October 17, 2023 (the "Effective Date"), is by and between Alkaline 88, LLC, an Arizona limited liability company with offices located at 8541 E. Anderson Drive, Suite 100, Scottsdale, AZ 85255 ("Licensor") and with Clean Bottling Inc., a Wyoming corporation with offices located at 6991 East Camelback Road B300, Scottsdale, AZ 85251 (referred to as "Licensee"). Licensor and Licensee each may be referred to hereinafter individually as a "party", or collectively as the "parties."
ContractAnd Distribution Agreement • May 5th, 2020
<DOCUMENT> <TYPE>EX-10.1.22 <SEQUENCE>27 <FILENAME>exh10122f.txt <TEXT> [EXHIBIT 10.1.22] FINANCING, PRODUCTION AND DISTRIBUTION AGREEMENT "Tournament of Dreams" Dated: As of July 25,2003 This Financing, Production and Distribution Agreement (this "Agreement") is entered into between CMX PRODUCTIONS, INC. ("CMX") and MIRACLE ENTERTAINMENT, INC. ("MEI") in connection with the Picture (as defined below). For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 1. Picture: The "Picture" shall (i) be based on the screenplay entitled "Tournament of Dreams" written by Don Abemathy ( any and all drafts and version thereof, now or hereafter existing, and all characters contained therein, the "Screenplay"), (ii) be directed by Don Abemathy (or a mutually approved replacement) and produced by John Daly ("Daly") and Jon Gentile ("Gentile"), (iii) be a first-class theatrical feature-length color 35mm live-action motion picture
EXCLUSIVE SUPPLY AND DISTRIBUTION AGREEMENTAnd Distribution Agreement • July 30th, 2021 • CytoDyn Inc. • Pharmaceutical preparations
This Exclusive Supply and Distribution Agreement (“Agreement”), made and entered into this 15th day of April, 2021 (“Effective Date”), by and between:
AMENDMENT #2 TO EXCLUSIVE LEAD SHARING AND DISTRIBUTION AGREEMENTAnd Distribution Agreement • May 1st, 2017 • Mazor Robotics Ltd. • Surgical & medical instruments & apparatus
THIS AMENDMENT TO EXCLUSIVE LEAD SHARING AND DISTRIBUTION AGREEMENT (this “Amendment”) is made effective as of this 22 day of December, 2016 (the “Amendment Effective Date”) by and between Mazor Robotics Ltd., with a principal office located at 7 HaEshel Street, Caesarea Park South, Israel 3088900 (“Mazor”) and Medtronic Navigation, Inc., having a principal office located at 826 Coal Creek Circle, Louisville, CO 80027 (“Medtronic” and, together with Mazor, the “Parties”) to that certain Exclusive Lead Sharing and Distribution Agreement (the “Agreement”) entered into effective as of May 18, 2016 (the “Agreement Effective Date”).
ContractAnd Distribution Agreement • May 5th, 2020 • New York
EX-10.3 4 exhibit10_3nonexclusive.htm EXHIBIT 10.3 NON-EXCLUSIVE LICENSE, MARKETING AND DISTRIBUTION AGREEMENT Non-Exclusive License, Marketing and Distribution Agreement Execution Version Non-Exclusive License, Marketing and Distribution Agreement Dated As Of September 29, 2006 Between Inverness Medical Innovations, Inc. And Chembio Diagnostic Systems, Inc. Table of Contents
SECOND AMENDMENT OF THE LICENSE, DEVELOPMENT, SUPPLY AND DISTRIBUTION AGREEMENTAnd Distribution Agreement • February 28th, 2013 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations • New York
This SECOND AMENDMENT OF THE LICENSE, DEVELOPMENT, SUPPLY AND DISTRIBUTION AGREEMENT (this “Second Amendment”) is made and effective as of January 29, 2013 (the “Second Amendment Effective Date”) by and among Allergan Sales, LLC, a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan Sales”), Allergan USA, Inc., a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan USA”), Allergan, Inc., a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan, Inc.” and, collectively with Allergan Sales and Allergan USA, “Allergan”) and Spectrum Pharmaceuticals, Inc. (“Spectrum”), a Delaware corporation with its principal place of business at 11500 S. Eastern Avenue, Henderson, Nevada 89052. Allergan and Spectrum are collectively referred to herein as the “Parties” and individually as a “Party”.
LICENSE, DEVELOPMENT, SUPPLY AND DISTRIBUTION AGREEMENTAnd Distribution Agreement • March 19th, 2018 • Oncolytics Biotech Inc • Pharmaceutical preparations • Hong Kong
Oncolytics and Licensee are referred to from time to time herein individually as a “Party” or collectively as the “Parties”.
RECITALS, and Distribution Agreement • October 26th, 1995 • Sequoia Systems Inc • Services-computer integrated systems design • Massachusetts
EX-4.1 5 d738703dex41.htm EX-4.1 SPIN-OFF AND DISTRIBUTION AGREEMENTAnd Distribution Agreement • May 5th, 2020
SPIN-OFF AND DISTRIBUTION AGREEMENT, dated as of December , 2014 (this “Agreement”), by and between Israel Corporation Ltd., a company incorporated with limited liability organized under the laws of the State of Israel (“IC”), and Kenon Holdings Ltd., a company wholly-owned by IC, with limited liability organized under the laws of Singapore (“Kenon”). Each of IC and Kenon is sometimes referred to herein as a “Party” and together, as the “Parties”). Capitalized terms used herein and not otherwise defined shall have the respective meanings assigned to them in Appendix 1.
ContractAnd Distribution Agreement • May 5th, 2020
<DOCUMENT> <TYPE>EX-10.22 <SEQUENCE>3 <FILENAME>dex1022.txt <DESCRIPTION>SUPPLY AND DISTRIBUTION AGREEMENT <TEXT> <PAGE> EXHIBIT 10.22 -------------------------------------------------------------------------------- SUPPLY AND DISTRIBUTION AGREEMENT -------------------------------------------------------------------------------- 1. PARTIES This Agreement is made between VIRAGEN INTERNATIONAL, INC. having its principal address at 865 SW 78th Avenue, Suite 100, Plantation, FL 33324 and VIRAGEN (SCOTLAND) LTD. having its principal address at Pentland Science Park, Bush Loan, Peniculk, Midlothian EH260 PPZ, UNITED KINGDOM, hereinafter referred to as "the Company" and HARVESTER TRADING CO., LTD., having its principal address at 311, Tung Hua N. Road, Taipei, Taiwan, R.O.C. hereinafter referred to as "the Distributor". 2. PURPOSE The purpose of this Agreement is to grant the Distributor the exclusive right to market, sell and distribute the Product within the Territory as defined in Exhibit
EXCLUSIVE SUPPLY AND DISTRIBUTION AGREEMENTAnd Distribution Agreement • July 30th, 2021 • CytoDyn Inc. • Pharmaceutical preparations • New Jersey
This Exclusive Supply and Distribution Agreement (“Agreement”), made and entered into this 11th day of May, 2021 (“Effective Date”), by and between:
NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY “[***]” ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS...And Distribution Agreement • November 30th, 2007 • Directed Electronics, Inc. • Household audio & video equipment
AMENDMENT, dated as of July 17, 2007 (this “Amendment”), to the Manufacturing and Distribution Agreement, dated as of April 7, 2005 (the “Agreement”), between SIRIUS SATELLITE RADIO INC., a Delaware corporation (“Sirius”), and DIRECTED ELECTRONICS, INC., a Florida corporation (“Directed”), as amended.
Portions of the exhibit have been excluded because it is both not material and is the type of information that the registrant treats as private or confidential. COMMERCIALIZATION AND DISTRIBUTION AGREEMENTAnd Distribution Agreement • March 17th, 2023 • Capricor Therapeutics, Inc. • Pharmaceutical preparations • New York
This Commercialization and Distribution Agreement (“Agreement”) is made and entered into as of the 10th day of February, 2023 (“Effective Date”), by and between CAPRICOR THERAPEUTICS, INC., a corporation organized under the laws of the State of Delaware, with its principal office located at 10865 Road to the Cure, Ste. 150, San Diego, California 92121 USA (“Capricor”) and NIPPON SHINYAKU CO., LTD. a corporation organized under the laws of Japan, with its principal office located at 14, Nishinosho-Monguchi-cho, Kisshoin, Minami-ku, Kyoto 601-8550, Japan (“Distributor”). Capricor and Distributor may sometimes individually be referred to herein as a “Party” and together as the “Parties”.
EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTHAnd Distribution Agreement • June 29th, 2022 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations • Delaware
THIS LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT is made as of July 20, 2021 (the “Effective Date”), by and between ELITE PHARMACEUTICALS, INC. a Nevada corporation and ELITE LABORATORIES, INC., a Delaware corporation located at 165 Ludlow Avenue, Northvale, New Jersey 07647 (collectively, “ELITE”), and LANNETT COMPANY, INC., USA, a Delaware corporation located at 9000 State Road, Philadelphia, PA 19136 and/or its Affiliates (“LANNETT”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. [*****] indicates the redacted confidential portions of this...And Distribution Agreement • February 26th, 2020 • Kamada LTD • Pharmaceutical preparations
This SIXTH Amendment to the Exclusive Manufacturing, Supply and Distribution Agreement dated August 23rd, 2010 as amended on September 6th, 2012, May 14th, 2013, February 15th, 2014, August 25th, 2015, and September 30th, 2016, by and between Baxalta US Inc., a member of the Takeda group of companies, having a place of business at 1200 Lakeside Dr., Bannockburn, IL 60015, USA (hereinafter “Baxalta”) and Kamada Ltd., having a place of business at 2 Holzman Street, Weizmann Science Park, Rehovot 7670402, Israel (hereinafter “Kamada”) (the “Agreement”) is entered into as of this 30th day of August, 2019 (the “Effective Date”). Baxalta and Kamada shall collectively be referred to as the “Parties”.
1 EXHIBIT 10.8 AMENDMENT TO LICENSE, SUPPLY AND DISTRIBUTION AGREEMENTAnd Distribution Agreement • August 16th, 1999 • Minimed Inc • Orthopedic, prosthetic & surgical appliances & supplies
AMENDMENT # 1 TO EXCLUSIVE LEAD SHARING AND DISTRIBUTION AGREEMENTAnd Distribution Agreement • May 1st, 2017 • Mazor Robotics Ltd. • Surgical & medical instruments & apparatus
THIS AMENDMENT # 1 TO EXCLUSIVE LEAD SHARING AND DISTRIBUTION AGREEMENT (this “Amendment”) is made effective as of this 24 day of October, 2016 (the “Effective Date”) by and between Mazor Robotics Ltd., with a principal office located at 7 HaEshel Street, Caesarea Park South, Israel 3088900 (“Mazor”) and Medtronic Navigation, Inc., having a principal office located at 826 Coal Creek Circle, Louisville, CO 80027 (“Medtronic” and, together with Mazor, the “Parties”) to that certain Exclusive Lead Sharing and Distribution Agreement (the “Agreement”) entered into effective as of May 18, 2016.
Contract, and Distribution Agreement • March 7th, 2024 • Evolus, Inc. • Pharmaceutical preparations • England and Wales
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]”.
ContractAnd Distribution Agreement • February 27th, 2013 • Viropharma Inc • Pharmaceutical preparations
Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.
